



(51) International Patent Classification:

C07K 5/06 (2006.01) *A61K 47/48* (2006.01)
C07K 5/065 (2006.01) *A61P 31/12* (2006.01)
C07K 5/09 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2013/021816

(22) International Filing Date:

17 January 2013 (17.01.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/588,154 18 January 2012 (18.01.2012) US

(71) Applicant: **FIRESTONE, Raymond, A** [US/US]; 330 West 72 St., Apt. 10A, New York, NY 10023 (US).

(74) Agent: **ZHANG, Yin, Philip**; Milstein Zhang & Wu LLC, 2000 Commonwealth Ave., Suite 400, Newton, MA 02466 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

19 September 2013



WO 2013/109675 A3

(54) Title: COMPOSITIONS AND METHODS FOR TREATING CANCER AND INFLAMMATION-RELATED DISEASES AND CONDITIONS

(57) Abstract: The invention provides di-peptide conjugated antitumor agents, pharmaceutical compositions and methods for preparation and use thereof for treating various cancer and inflammation-related diseases and conditions. The present invention addresses the shortcomings of the existing anti-tumor and anti-inflammatory drugs, particularly in that the anti-tumor agents of the invention that selectively kill cancer cells with minimal damage to normal cells. Similarly, the anti-inflammatory agents of the invention provide effective treatment of various inflammatory diseases and conditions without the many deleterious side effects commonly associated with steroids

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 2013/021816

A. CLASSIFICATION OF SUBJECT MATTER		<i>C07K 5/06 (2006.01)</i> <i>C07K 5/065 (2006.01)</i> <i>C07K 5/09 (2006.01)</i> <i>A61K 47/48 (2006.01)</i> <i>A61P 31/12 (2006.01)</i> <i>A61P 35/00 (2006.01)</i>
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
C07K 5/06, 5/065, 5/09, A61K 47/48, A61P 31/12, 35/00		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
Google, Esp@cenet, PatSearch (RUPTO internal), RUPAT, STN Online, SCOPUS, USPTO		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 1998/013059 A1 (BRISTOL-MYERS SQUIBB COMPANY) 02.04.1998, abstract, examples, p. 12, lines 3-27, claims 45-47, fig. 2, 3, 5	1-10, 12-14, 16-25, 37, 38, 40-46, 48, 49, 61, 62, 64-75
Y		11, 15, 26-36, 39, 47, 50-60, 63, 76
X	DUBOWCHIK G.M. et al. Cathepsin B-sensitive dipeptide prodrugs. I.A model study of structural requirements for efficient release of doxorubicin. Bioorganic & Medicinal Chemistry Letters, 1998, v.8, pp. 3341-3346, especially scheme 1, scheme 2, compound 29	1-10, 12-14, 16-25, 37, 38, 40-46, 48, 49, 61, 62, 64-75
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier document but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search		Date of mailing of the international search report
07 May 2013 (07.05.2013)		27 June 2013 (27.06.2013)
Name and mailing address of the ISA/ FIPS Russia, 123995, Moscow, G-59, GSP-5, Berezhkovskaya nab., 30-1		Authorized officer T. Gladysenko
Facsimile No. +7 (499) 243-33-37		Telephone No. (495)531-64-81

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 2013/021816

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SHAO, Li-Hua et al. Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis. Cancer, 2011 [online] Retrieved from the Internet: <URL: http: www.znhospital.cn/tsysfiles/教学/.../209%20Shao%20LH-Cancer.pdf >, pp. 3-10	1-10, 12-14, 16-25, 37, 38, 40-46, 48, 49, 61, 62, 64-75
Y	WO 2010/069069 A1 (MERCK FROSST CANADA LTD. et al.) 24.06.2010, p. 1, lines 20-25, p. 10	11, 15, 26-36, 39, 47, 50-60, 63, 76